Asthma and Rhinitis Induced by Selective Immediate Reactions to Paracetamol and Non-steroidal Anti-inflammatory Drugs in Aspirin Tolerant Subjects by Diana Pérez-Alzate et al.
fphar-07-00215 July 18, 2016 Time: 13:7 # 1
ORIGINAL RESEARCH
published: 20 July 2016
doi: 10.3389/fphar.2016.00215
Edited by:
Ulrich M. Zanger,
Dr. Margarete Fischer-Bosch-Institute
of Clinical Pharmacology, Germany
Reviewed by:
Colin Ross,
The University of British Columbia,
Canada
Frank A. Redegeld,
Utrecht University, Netherlands
*Correspondence:
Miguel Blanca
mblancago@gmail.com
Specialty section:
This article was submitted to
Pharmacogenetics and
Pharmacogenomics,
a section of the journal
Frontiers in Pharmacology
Received: 17 February 2016
Accepted: 04 July 2016
Published: 20 July 2016
Citation:
Pérez-Alzate D, Blanca-López N,
Doña I, Agúndez JA,
García-Martín E, Cornejo-García JA,
Perkins JR, Blanca M and Canto G
(2016) Asthma and Rhinitis Induced
by Selective Immediate Reactions
to Paracetamol and Non-steroidal
Anti-inflammatory Drugs in Aspirin
Tolerant Subjects.
Front. Pharmacol. 7:215.
doi: 10.3389/fphar.2016.00215
Asthma and Rhinitis Induced by
Selective Immediate Reactions to
Paracetamol and Non-steroidal
Anti-inflammatory Drugs in Aspirin
Tolerant Subjects
Diana Pérez-Alzate1, Natalia Blanca-López1, Inmaculada Doña2, José A. Agúndez3,
Elena García-Martín3, José A. Cornejo-García2,4, James R. Perkins4, Miguel Blanca2*
and Gabriela Canto1
1 Allergy Service, Infanta Leonor University Hospital, Madrid, Spain, 2 Allergy Unit, IBIMA-Regional University Hospital of
Malaga-UMA, Málaga, Spain, 3 Department of Pharmacology, University of Extremadura, Caceres, Spain,
4 Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA, Málaga, Spain
In subjects with non-steroidal anti-inflammatory drugs (NSAIDs)- exacerbated
respiratory disease (NERD) symptoms are triggered by acetyl salicylic acid (ASA) and
other strong COX-1 inhibitors, and in some cases by weak COX-1 or by selective
COX-2 inhibitors. The mechanism involved is related to prostaglandin pathway inhibition
and leukotriene release. Subjects who react to a single NSAID and tolerate others
are considered selective responders, and often present urticaria and/or angioedema
and anaphylaxis (SNIUAA). An immunological mechanism is implicated in these
reactions. However, anecdotal evidence suggests that selective responders who
present respiratory airway symptoms may also exist. Our objective was to determine
if subjects might develop selective responses to NSAIDs/paracetamol that manifest
as upper/lower airways respiratory symptoms. For this purpose, we studied patients
reporting asthma and/or rhinitis induced by paracetamol or a single NSAID that tolerated
ASA. An allergological evaluation plus controlled challenge with ASA was carried out. If
ASA tolerance was found, we proceeded with an oral challenge with the culprit drug. The
appearance of symptoms was monitored by a clinical questionnaire and by measuring
FEV1 and/or nasal airways volume changes pre and post challenge. From a total of 21
initial cases, we confirmed the appearance of nasal and/or bronchial manifestations in
ten, characterized by a significant decrease in FEV1% and/or a decrease in nasal volume
cavity after drug administration. All cases tolerated ASA. This shows that ASA tolerant
subjects with asthma and/or rhinitis induced by paracetamol or a single NSAID without
skin/systemic manifestations exist. Whether these patients represent a new clinical
phenotype to be included within the current classification of hypersensitivity reactions
to NSAIDs requires further investigation.
Keywords: hypersensitivity, paracetamol, non-steroidal anti-inflammatory drugs, immediate allergy, asthma,
rhinitis
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INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) are the
most frequent elicitors of drug hypersensitivity reactions
(DHRs) (Doña et al., 2012; Jares et al., 2015), being able to
provoke reactions with immunological and non-immunological
mechanisms (Cornejo-Garcia et al., 2009). NSAID-DHRs are
now considered more frequent than betalactam (BL) DHRs,
which largely induce immunologically mediated reactions
(Antúnez et al., 2006b).
Since the asthma triad was first reported (Widal et al., 1993;
Samter and Beers, 1968), a considerable amount of work has been
dedicated to the study of ASA-induced airways disease (Pleskow
et al., 1983; Szczeklik et al., 2001; Stevenson, 2004). ASA and
other NSAIDs can induce various clinical entities via two major
mechanisms (Kowalski et al., 2011; Asero et al., 2013; Stevenson
and Kowalski, 2013). The first mechanism is pharmacological,
where individuals react to chemically unrelated NSAIDs (cross
intolerance), whereas the second mechanism is immune-
mediated, thought to be related to specific IgE antibodies or
sensitized T cells (selective reactions, SRs) (Kowalski et al., 2013).
Entities in the former category are generally more frequent
(Canto et al., 2009; Doña et al., 2011, 2012) and pharmacogenetic
studies have been conducted for patients with respiratory airways
(Ayuso et al., 2015) and cutaneous involvement (Cornejo-García
et al., 2012, 2013). These studies are opening new avenues toward
an understanding of the mechanisms involved (Perkins et al.,
2015).
NSAIDs-exacerbated respiratory disease (NERD) belongs
to the cross intolerance category and consists of chronic
rhinosinusitis, nasal polyposis and/or bronchial asthma. These
entities may appear in isolation but usually present together
(Stevenson, 2004; Kowalski et al., 2013). They are aggravated by
ASA and other strong COX-1 inhibitors, although intolerance
of weak COX-1 and selective COX-2 inhibitors can also occur
(Pleskow et al., 1983; Szczeklik et al., 2001; Stevenson and
Kowalski, 2013). Although these patients may initially develop
symptoms with different NSAIDs, a hallmark of NERD is the
elicitation of a reaction after ASA intake (Asero et al., 2013;
Kowalski et al., 2013).
Paracetamol is also responsible for respiratory reactions and
can be a risk factor for asthma (Blanca-López et al., 2015)
development, although the underlying mechanisms are currently
unknown (Lesko, 2002).
Few studies have examined individuals who react to a single
NSAID or paracetamol but tolerate ASA (Corominas et al.,
2012). Nevertheless, the existence of this type of response has
been shown (Cavkayter et al., 2015). One of the problems when
studying this entity is that respiratory airways involvement may
occur during an anaphylactic reaction to a single NSAID (Doña
et al., 2011; Ayuso et al., 2013).
In this study, we present a series of cases who reported
isolated upper and/or lower respiratory symptoms after
taking a COX-1 or selective COX-2 inhibitor, but tolerated
other NSAIDs including ASA. Diagnosis was confirmed by
controlled challenge with the culprit drug and proving ASA
tolerance.
MATERIALS AND METHODS
Patient Selection
Patients reporting a respiratory reaction but no other symptoms
after NSAIDs or paracetamol intake were evaluated in two centers
integrated into the Spanish National Network for the Study of
Drug and Allergen Hypersensitivity (Infanta Leonor University
Hospital in Madrid, and Regional University Hospital of Malaga).
A prerequisite for inclusion was that the patient reported ASA
tolerance – this was then confirmed by ASA challenge in this
study. In addition, challenge with the culprit drug was performed
to confirm the diagnosis of a selective respiratory reaction (Doña
et al., 2011, 2012). We did not include subjects with chronic
spontaneous urticaria, nasal polyposis, respiratory infections,
autoimmune diseases, pregnancy or who were undergoing breast-
feeding.
This study was performed according to the principles of
the Declaration of Helsinki and approved by the local ethics
committee from the Infanta Leonor University Hospital and
the Regional University Hospital of Malaga. All patients were
informed orally about the study and signed the corresponding
informed consent.
Clinical Evaluation
Patients were subjected to a clinical questionnaire, skin prick
testing (SPT) and had total serum IgE levels measured. Nasal
and bronchial symptoms were assessed as described (Doña
et al., 2011; Campo et al., 2013). Symptoms attributable to
foods, hymenoptera sting and potential drug allergies were also
recorded. A panel of 30 common inhalant and food allergens
prevalent in the area of study was used for skin testing. A wheal
diameter larger than 3 mm was considered positive. A negative
saline control was also used.
Nasal acoustic rhinomanometry was performed and basal
FEV1 estimated (Campo et al., 2013). Nasal exploration including
a CT scan was also performed to exclude patients with polyposis,
chronic rhinosinusitis or any other underlying nasal disease.
Nasal Challenge with Lysine-Aspirin
(lys-ASA)
Nasal challenge with lys-ASA was performed as described
(Lee et al., 2004; Nizankowska-Mogilnicka et al., 2007). The
appearance of nasal symptoms plus a decrease of 30% in the total
volume of both nasal cavities measured by acoustic rhynometry
(AR) was considered a positive result. The response of the
lower airways after nasal challenge was also monitored by FEV1.
A decrease greater than 12% compared to basal values was
considered positive (Campo et al., 2013).
Oral Provocation with ASA
This was performed using a single blind procedure as described
(Doña et al., 2011), with the following modifications: on the
first day, we administered placebo and if no reaction occurred,
increasing oral concentrations of ASA were given at intervals of
90 min (doses of 25, 100, and 250 mg; cumulative dose of 375 mg).
If no symptoms appeared, we repeated the challenge 1 week later
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but with a starting dose of 500 mg of ASA; if this was tolerated
another 500 mg dose was given 90 min later (cumulative dose of
1000 mg).
Oral Provocation with the Culprit Drug
When using the suspected culprit drug, we started with lower
concentrations, following previous recommendations (Doña
et al., 2011). For ibuprofen, increasing doses of 5, 20, 75, 150,
and 350 mg were given at 45-minute intervals. If symptoms
appeared at any time the procedure was stopped immediately.
Clinical symptoms were assessed and changes in nasal flow
were monitored by acoustic rhynomanometry; lower airways
involvement was monitored by FEV1. For paracetamol the
same approach was used but with doses of 5, 20, 50, 75, 150,
and 200 mg. If symptoms did not appear, another 500 mg
of paracetamol were given (cumulative dose of 1000 mg). For
rofecoxib, we used doses of 5, 15, 40, and 60 mg (cumulative dose
of 120 mg), whereas for dexketoprofen, we used doses of 5, 20,
and 25 mg (cumulative dose of 50 mg).
RESULTS
A total of 21 patients reporting symptoms of rhinitis and/or
asthma after the intake of paracetamol or a single NSAID, but
also reporting ASA tolerance were prospectively recruited from
January 2010 to December 2014. In all patients ASA tolerance was
also assessed by challenge as described in the Methods section.
After completing the study, nasal and/or lower airways
symptoms attributable to the intake of the culprit drug could be
confirmed for 10 patients (Table 1). There was no clear difference
in gender (four were female; six male). Their ages ranged from 22
to 69 years old, with a mean of 51.5. In terms of atopy, six were
atopic and four non-atopic. The mean number of episodes was
4.3, although this value ranged from 2 to 10 amongst patients.
Ibuprofen was involved in four cases, paracetamol in 4,
desketoprofen in 1 and etoricoxib in 1 (Table 1). Most patients
reported three or more previous episodes (except patients 7 and
10, who reported only 2 previous episodes). Rhinitis, with or
without asthma, appeared in six patients whereas isolated asthma
occurred in four. Concerning atopic status, six patients showed
a positive SPT to more than one common inhalant allergen
(Table 1). No positive SPT to food allergens was observed.
Clinical entities and the time interval elapsed between drug intake
and appearance of symptoms according to patient history are
provided in Table 1, whereas Table 2 shows the challenge results.
Although statistical comparisons were not performed due to
the limited number of patients, we observed a tendency for
ibuprofen to induce a reaction at higher doses and after longer
time intervals compared to paracetamol (Table 2).
Concerning the cumulative dose required to elicit the reaction,
this was variable for each drug (Table 2). For three patients the
response to ibuprofen appeared at a dose of less than half the
therapeutic dose; this also occurred in three patients who reacted
to paracetamol.
DISCUSSION
In this study, we have presented for the first time a series
of patients with SRs to paracetamol or a single NSAID with
exclusive respiratory airway involvement. The approach for
identifying these patients was based on clinical history, negative
challenge with ASA and positive challenge with the culprit drug.
Of the 21 cases initially considered, ten could be confirmed as
tolerating asthma but reacting to the culprit drug. On average,
TABLE 1 | Clinical characteristics and drugs involved.
Patient
No.
Sex Age
(years)
Atopy Positive allergen SPT Serum specific
IgE (kU/l)
Culprit drug No. of
episodes
Time interval
(min)
Reaction
1 F 47 + Phleum pratense
Lollium perenne
2.15
1.65
Dexketoprofen 3 20–30 Asthma
2 F 22 + Lollium perenne 1.55 Etoricoxib 3 30–60 Rhinitis
3 F 69 + Alternaria alternata
Aspergillus fumigatus
1.31
11.7
Ibuprofen 6 30–60 Rhinitis
4 M 38 + Dermatophagoides
pteronyssinus
Olea europaea
1.25
1.95
Ibuprofen 7 60–120 Rhinitis + Asthma
5 M 65 − NA NA Ibuprofen 3 60–120 Rhinitis + Asthma
6 F 47 + Dermatophagoides
pteronyssinus
Alternaria alternata
Aspergillus fumigatus
2.34
1.25
1.45
Ibuprofen 4 60–120 Rhinitis + Asthma
7 M 66 − NA NA Paracetamol 2 20–30 Asthma
8 M 50 + Olea europaea
Lollium perenne
Cat dander
1.23
3.23
1.60
Paracetamol 10 20–30 Asthma
9 M 35 − NA NA Paracetamol 3 30–60 Asthma
10 M 56 − NA NA Paracetamol 2 30–60 Rhinitis
NA, not applicable.
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TABLE 2 | Results of challenge: time intervals between drug
administration and the appearance of clinical symptoms, last and
cumulative doses, and clinical symptoms induced.
Patient No. Culprit drug No. of
episodes
Time interval
(min)
Reaction
1 Dexketoprofen 3 20–30 Asthma
2 Etoricoxib 3 30–60 Rhinitis
3 Ibuprofen 6 30–60 Rhinitis
4 Ibuprofen 7 60–120 Rhinitis + Asthma
5 Ibuprofen 3 60–120 Rhinitis + Asthma
6 Ibuprofen 4 60–120 Rhinitis + Asthma
7 Paracetamol 2 20–30 Asthma
8 Paracetamol 10 20–30 Asthma
9 Paracetamol 3 30–60 Asthma
10 Paracetamol 2 30–60 Rhinitis
AR, acoustic rhynometry; FEV1, forced expiratory volume in 1 s; DPT, drug
provocation test.
these patients were older than the eleven other cases and reported
more previous episodes.
Selective reactions to NSAIDs have been reported by several
groups and for all available NSAIDs and selective COX-2
inhibitors (reviewed in Canto et al., 2009; Cornejo-Garcia
et al., 2009; Blanca-Lopez et al., 2014; Torres et al., 2014).
Pyrazolones, although not considered NSAIDs, are common
triggers (Kowalski et al., 2013; Demir et al., 2015); other
important drugs include diclofenac (Gala et al., 1998; Del Pozo
et al., 2000; Harrer et al., 2010; Picaud et al., 2014), ibuprofen
(Koransky et al., 2016), as well as weak COX-1 (Vidal et al., 1997;
Astarita et al., 2011), and COX-2 inhibitors (Fontaine et al., 2005;
Chamberlin and Silverman, 2009). In fact, in some countries
SRs are responsible for up to 50% of all NSAID-DHRs (Demir
et al., 2015). However, in these reported cases the symptoms
induced were anaphylaxis and/or urticaria, and in those reactions
with respiratory airway involvement, other organs were also
implicated (Doña et al., 2011). All patients included in this
study developed respiratory symptoms only, i.e., nasal symptoms
and/or AR/FEV1 decreases, without other organ involvement.
For pyrazolones, positive skin and/or basophil activation test
results have been found with metamizole (Gomez et al., 2009),
providing indirect evidence of a potential IgE-mediated reaction.
However, the only pyrazolone for which specific IgE-mediated
reactions have been demonstrated is propyphenazone (Himly
et al., 2003). Positive skin tests results for other NSAIDs are
almost anecdotal with very few cases reported (Canto et al., 2009).
Consequently, we did not perform skin testing with the culprit
drug here.
Considering cross intolerance reactions, patients may present
both respiratory and cutaneous involvement (blended reactions)
(Stevenson and Kowalski, 2013), which have been reported as
being more frequent than cases with exclusively respiratory
symptoms (Doña et al., 2011). Questions remain as to whether
blended reactions constitute a well-defined entity or a more
heterogeneous group. Our feeling is that this entity includes
different phenotypes (Ayuso et al., 2013).
Concerning respiratory SRs, only one case has been reported
in the literature so far (Corominas et al., 2012). Repeated
episodes of bronchospasm induced by paracetamol occurred in
a 19-year-old atopic woman, who tolerated 500 mg of ASA.
After the intake of 500 mg of paracetamol she presented a severe
episode of bronchospasm with a decrease in FEV1 that required
treatment with salbutamol (Corominas et al., 2012). Although
the existence of respiratory SRs has been suggested previously
(Cavkayter et al., 2015), this pattern of reaction has not been
clearly identified. The identification of these reactions may be
complicated due to respiratory symptoms being accompanied
with mild symptoms in other organs: these reactions may be
hard to distinguish from anaphylactic reactions. In fact, in IgE-
mediated DHRs an initial mild reaction can be followed by
a more severe one after subsequent exposure (Antúnez et al.,
2006a). This phenomenon is thought to be due to greater
levels of IgE antibodies and increased affinity. For the patients
reported here, no evidence for increasing reaction severity
was found.
Summarizing, in this study, we have presented a group of
patients with an unusual pattern of response, which does not fit
properly in the current classification system of DHRs to NSAIDs
(Ayuso et al., 2013; Kowalski et al., 2013; Agúndez et al., 2015).
Further attempts are underway to identify more patients with
these characteristics and potentially establish the mechanisms
involved.
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